Financials

  • Market Capitalization 3.46 B
  • Employee 562
  • Founded 2012
  • CEO Carl Hansen
  • Website www.abcellera.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00LLW2MF2
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-14.54
Price to sales ratio
35.55

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
1568
RCUS
Arcus Biosciences, Inc. Common Stock
28.69 USD-1.71%-6.30%+2.91%+171.69%3.65 B USD
1580
IOVA
Iovance Biotherapeutics, Inc. - Common Stock
7.94 USD-0.87%-1.73%+93.66%+262.56%3.60 B USD
1610
VCYT
Veracyte, Inc. - Common Stock
43.03 USD-0.72%+3.66%-7.18%+16.61%3.46 B USD
1642
QURE
uniQure N.V. - Ordinary Shares
47.86 USD-1.77%+1.27%+9.59%+193.98%3.32 B USD

Frequently asked questions about AbCellera Biologics Inc. Common Shares

What is the AbCellera Biologics Inc. Common Shares stock price today?

The current price of AbCellera Biologics Inc. Common Shares (ABCL) is 11.30. Over the past 24 hours, the stock has changed by -0.44%. Follow the ABCL chart for real-time price dynamics.

What is the stock ticker of AbCellera Biologics Inc. Common Shares?

AbCellera Biologics Inc. Common Shares trades under the ticker ABCL. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is AbCellera Biologics Inc. Common Shares stock going up?

ABCL has changed by +6.00% over the last week, +98.25% over the last month, and +175.61% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of AbCellera Biologics Inc. Common Shares?

AbCellera Biologics Inc. Common Shares currently has a market capitalization of 3.46 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were AbCellera Biologics Inc. Common Shares earnings last quarter?

Last quarter, AbCellera Biologics Inc. Common Shares reported earnings of -0.18 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was AbCellera Biologics Inc. Common Shares revenue for the last quarter?

AbCellera Biologics Inc. Common Shares reported quarterly revenue of 4.05 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was AbCellera Biologics Inc. Common Shares net income for the last quarter?

AbCellera Biologics Inc. Common Shares reported net income of -55.43 M for the last quarter. The previous quarter showed -43.16 M, which means net income changed by -28.41%.

How many employees does AbCellera Biologics Inc. Common Shares have?

As of the latest available data, AbCellera Biologics Inc. Common Shares has 562 employees. Workforce size can provide additional context about the company's scale and operations.

What is AbCellera Biologics Inc. Common Shares EBITDA?

AbCellera Biologics Inc. Common Shares EBITDA is -55.79 M, and its EBITDA margin is -1 377.46%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy AbCellera Biologics Inc. Common Shares stock?

You can buy AbCellera Biologics Inc. Common Shares (ABCL) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in AbCellera Biologics Inc. Common Shares stock?

Investing in AbCellera Biologics Inc. Common Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ABCL chart and related analysis on metatrader.com as part of your research.

AbCellera Biologics Inc. - Common Shares

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

News